

ADDITIONAL RISK MINIMISATION COMMUNICATION PLAN	
Medicinal product(s)/active substance(s)	<ol style="list-style-type: none"> 1. Glycopyrronium Bromide 1mg Tablets and Assicco 1mg Tablets 2. Glycopyrronium Bromide 1mg Tablets and Assicco 2mg Tablets
Marketing authorisation holder(s)	Morningside Healthcare Limited
Safety concern and purpose of the communication	<ol style="list-style-type: none"> 1. Checklist for Healthcare Professionals: To provide information on the administration of Glycopyrronium bromide tablets and management and minimisation of increased occurrence of anticholinergic side effects with the use of Glycopyrronium. 2. Patient Alert Card: To remind the carer of the correct dose of Glycopyrronium Bromide 1 mg and 2 mg tablets to be given to the patient and provide information on the management and minimisation of increased occurrence of anticholinergic side effects with the use of Glycopyrronium.
Educational Materials recipients	<ol style="list-style-type: none"> 1. Neurologists, 2. Paediatric neurologists, 3. Chief hospital pharmacists
Timetable	
Submission of the materials to MHRA for review	22-Mar-21
Method of dissemination of materials	<p>The 'checklist for healthcare professionals' and 'patient alert card' will be uploaded on eMC within 10 working days post approval from MHRA.</p> <p>A link to the materials uploaded on eMC will also be provided on the company website.</p>